Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

References

• Allen JE, Kline CLB, Prabhu VV, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016.https://doi.org/10.18632/oncotarget.11814.
   Google Scholar
• Allen JE, Krigsfeld G, Mayes PA, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013;5(171):171ra17.https://doi.org/10.1126/scitranslmed.3004828. PMID:23390247
   PubMed Web of Science ®Google Scholar
• Kline CL, Van den Heuvel APJ, Allen JE, et al. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2alpha kinases. Sci Signal. 2016;9(415):ra18.https://doi.org/10.1126/scisignal.aac4374. PMID:26884600
   PubMed Web of Science ®Google Scholar
• Ishizawa J, Kojima K, Chachad D, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016;9(415):ra17.https://doi.org/10.1126/scisignal.aac4380. PMID:26884599
   PubMed Web of Science ®Google Scholar
• Prabhu VV, Allen JE, Dicker DT, et al. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Res. 2015;75(7):1423–1432.https://doi.org/10.1158/0008-5472.CAN-13-3451. PMID:25712124
   PubMed Web of Science ®Google Scholar
• Prabhu VV, et al. ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples. Blood. 2014;124(21):5219.
   Web of Science ®Google Scholar
• Stein MN, Bertino JR, Kaufman HL, et al. First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017.https://doi.org/10.1158/1078-0432.CCR-16-2658.
   Google Scholar
• Arrillaga-Romany I, Chi AS, Allen JE, et al. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017.https://doi.org/10.18632/oncotarget.17837.
   PubMedGoogle Scholar
• Matthew EM, Zhou L, Yang Z, et al. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget. 2016;7(4):3662–3676.https://doi.org/10.18632/oncotarget.6657. PMID:26695546
   PubMed Web of Science ®Google Scholar
• Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111(7):3322–3330.https://doi.org/10.1182/blood-2007-09-078162. PMID:18362212
   PubMed Web of Science ®Google Scholar
• Pluta A, Wierzbowska A, Cebula-Obrzut B, et al. Prognostic value of inhibitor of apoptosis protein family expression in patients with acute myeloid leukemia. Leuk Lymphoma. 2015;56(9):2529–2535.https://doi.org/10.3109/10428194.2014.1003052. PMID:25549803
   PubMed Web of Science ®Google Scholar
• Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia. 2009;23(3):467–476.https://doi.org/10.1038/leu.2008.329. PMID:19039324
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos MA, Delasalle K, et al. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80(4):887–890. PMID:1498331
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Painuly U, Kimlinger T, et al. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia. 2014;28(7):1519–1528.https://doi.org/10.1038/leu.2014.2. PMID:24402161
   PubMed Web of Science ®Google Scholar
• Desplanques G, Giuliani N, Delsignore R, et al. Impact of XIAP protein levels on the survival of myeloma cells. Haematologica. 2009;94(1):87–93.https://doi.org/10.3324/haematol.13483. PMID:19001278
   PubMed Web of Science ®Google Scholar
• Ott MM, Bartkova J, Bartek J, et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood. 1997;90(8):3154–3159. PMID:9376597
   PubMed Web of Science ®Google Scholar
• Steensma DP. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes? Best Pract Res Clin Haematol. 2012;25(4):443–451.https://doi.org/10.1016/j.beha.2012.10.007. PMID:23200541
   PubMed Web of Science ®Google Scholar
• Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol. 2015;96(1):1–9.https://doi.org/10.1016/j.bcp.2015.04.008. PMID:25935605
   PubMed Web of Science ®Google Scholar
• Muz B, Ghazarian RN, Ou M, et al. Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther. 2016;10:217–226. PMID:26811670
   PubMed Web of Science ®Google Scholar
• Talekar MK, Allen JE, Dickerand DT, et al. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle. 2015;14(15):2422–2428.https://doi.org/10.1080/15384101.2015.1054086. PMID:26030065
   PubMed Web of Science ®Google Scholar
• Allen JE, Prabhu VV, Talekar M, et al. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015;75(8):1668–1674.https://doi.org/10.1158/0008-5472.CAN-14-2356. PMID:25681273
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang H, Ran L, et al. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. Biochem Biophys Res Commun. 2016;476(4):260–266.https://doi.org/10.1016/j.bbrc.2016.05.106. PMID:27233611
   PubMed Web of Science ®Google Scholar
• Karpel-Massler G, Bâ M, Shu C, et al. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget. 2015;6(34):36456–36471. PMID:26474387
   PubMedGoogle Scholar
• Kremer WB. Drugs five years later: cytarabine. Ann Intern Med. 1975;82(5):684–688.https://doi.org/10.7326/0003-4819-82-5-684. PMID:1056159
   PubMed Web of Science ®Google Scholar
• Weigert O, Pastore A, Rieken M, et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia. 2007;21(3):524–528.https://doi.org/10.1038/sj.leu.2404511. PMID:17268531
   PubMed Web of Science ®Google Scholar
• Kiziltepe T, Hideshima T, Catley L, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6(6):1718–1727.https://doi.org/10.1158/1535-7163.MCT-07-0010. PMID:17575103
   PubMed Web of Science ®Google Scholar
• Meja K, Stengel C, Sellar R, et al. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol. 2014;167(1):69–79.https://doi.org/10.1111/bjh.13013. PMID:24975213
   PubMed Web of Science ®Google Scholar
• Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19(3):657–667.https://doi.org/10.1158/1078-0432.CCR-11-1446. PMID:23251002
   PubMed Web of Science ®Google Scholar
• Taylor DJ, Parsons CE, Han H, et al. Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells. BMC Cancer. 2011;11:470.https://doi.org/10.1186/1471-2407-11-470. PMID:22044796
   PubMed Web of Science ®Google Scholar
• Kaminskyy VO, Surova OV, Vaculova A, et al. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis, 2011;32(10):1450–1458.https://doi.org/10.1093/carcin/bgr135. PMID:21771726
   PubMed Web of Science ®Google Scholar
• Eramo A, Pallini R, Lotti F, et al. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res. 2005;65(24):11469–11477.https://doi.org/10.1158/0008-5472.CAN-05-1724. PMID:16357155
   PubMed Web of Science ®Google Scholar
• Orozco JJ, Appelbaum FR. Unfavorable, complex, and monosomal karyotypes: the most challenging forms of acute myeloid leukemia. Oncology (Williston Park). 2012. 26(8):706–712. PMID:22957403
   PubMed Web of Science ®Google Scholar
• Takahashi K, Kantarjian H, Garcia-Manero G, et al. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2016;16(3):163–168 e1–2.https://doi.org/10.1016/j.clml.2015.11.016.
   Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520–525.https://doi.org/10.1093/annonc/mdn656. PMID:19074748
   PubMed Web of Science ®Google Scholar
• Raza S, Safyan RA, Rosenboum E et al. Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol. 2017;8(2):55–70.https://doi.org/10.1177/2040620716680548. PMID:28203342
   PubMed Web of Science ®Google Scholar